News from emd serono A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Jun 30, 2020, 18:45 ET FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that...
Jun 25, 2020, 08:00 ET EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms of Covid-19 Infection
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced the U.S. Food and Drug...
May 29, 2020, 08:02 ET New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that updated data from the...
May 27, 2020, 17:17 ET Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today the U.S. Food and Drug...
May 23, 2020, 02:00 ET New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced data on the long-term efficacy...
May 13, 2020, 19:40 ET Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced data for its innovative...
Apr 30, 2020, 08:00 ET Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced 25 abstracts will be presented at...
Apr 09, 2020, 06:00 ET EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced...
Mar 25, 2020, 03:00 ET TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the Japanese Ministry of...
Mar 13, 2020, 08:00 ET EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced an...
Jan 06, 2020, 07:00 ET BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the...
Nov 08, 2019, 08:00 ET EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced...
Oct 28, 2019, 14:00 ET European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that...
Oct 22, 2019, 08:00 ET Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced on behalf of the global strategic...
Oct 08, 2019, 11:24 ET EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that results from FORWARD, a...
Sep 27, 2019, 02:00 ET New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the...
Sep 20, 2019, 08:10 ET CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that...
Sep 10, 2019, 08:00 ET EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the initiation of two global...
Aug 28, 2019, 08:09 ET EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that it will present data on...
Jul 16, 2019, 09:00 ET EMD Serono's Embracing Carers™ Launches 'Time Counts' to Raise 1 Million Minutes of Support for Caregivers
EMD Serono, the biopharmaceutical company of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that its Embracing Carers™...
May 30, 2019, 09:02 ET EMD Serono Makes Multiple Sclerosis Visible This World MS Day and Beyond
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, joins the global multiple sclerosis (MS)...
May 28, 2019, 13:53 ET EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from its multiple sclerosis...
May 14, 2019, 19:44 ET FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients with advanced renal cell carcinoma...
May 10, 2019, 13:46 ET Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new 48-week results of the...
May 07, 2019, 08:00 ET EMD Serono Launches MS-LINK™, a Community to Advance MS Science and Improve Patient Lives
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the launch of MS-LINK™...
